AstraZeneca (AZN) is in talks regarding a potential partnership deal with Summit Therapeutics (SMMT) in which it could pay as much as $15B over time to license Summit’s ivonescimab lung-cancer treatment, people familiar with the matter told Bloomberg’s Michelle Davis and Dinesh Nair. Summit has also held discussions with other major pharmaceutical companies, the sources said.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics in talks for $15B AstraZeneca partnership, Bloomberg says
- Summit Therapeutics trading halted, volatility trading pause
- Strategic Collaboration and Growth Potential Drive Positive Outlook for Summit Therapeutics
- Summit Therapeutics initiated with a Buy at UBS
- Revolution Medicines, Summit Therapeutics enter clinical collaboration